论文部分内容阅读
liguzinediol是一种毒性较小[1],具有心脏安全性,可用于治疗急性心衰的化合物。它通过影响肌浆网钙释放,增加大鼠在体和离体的心脏收缩力[2-3],对正常大鼠及其离体心脏起到较好的正性肌力作用[4-5]。前期对liguzinediol在大鼠体内的药代动力学、♀♂差异及药物代谢进行了研究报道[6-8]。根据一类新药研制的要求,比格犬体内的药代动力学研究对指导临床具有更为重要
Liguzinediol is a less toxic [1] compound that has cardiac safety and can be used to treat acute heart failure. It affects calcium release from the sarcoplasmic reticulum and increases cardiac contractility in vivo and ex vivo [2-3], and plays a positive inotropic effect on normal rats and their isolated heart [4-5 ]. Pre-liguzinediol pharmacokinetics in rats, ♀ ♂ differences and drug metabolism were reported [6-8]. According to the requirements of a new type of drug development, beagle dogs pharmacokinetic studies in vivo is more important to guide the clinical